Scisparc Ltd
NASDAQ:SPRC
Scisparc Ltd
Inventory
Scisparc Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Inventory
$110k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Inventory
$85.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Inventory
$8.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Scisparc Ltd
Glance View
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
See Also
What is Scisparc Ltd's Inventory?
Inventory
110k
USD
Based on the financial report for Dec 31, 2024, Scisparc Ltd's Inventory amounts to 110k USD.
What is Scisparc Ltd's Inventory growth rate?
Inventory CAGR 1Y
-85%
Over the last year, the Inventory growth was -85%.
